All News

Treatment regimens consisting of daclatasvir plus sofosbuvir plus ribavirin and velpatasvir/sofosbuvir plus ribavirin show similar cure rates in patients with hepatitis C virus genotype 2 and 3.

Elotuzumab (Empliciti) with pomalidomide and dexamethasone (Pd) is the first triplet combination to be approved based on a randomized clinical trial using Pd as a comparator.

Officials with the FDA have approved elotuzumab (Empliciti) injection for intravenous use in combination with pomalidomide and dexamethasone for the treatment of certain patients with relapsed or refractory multiple myeloma.

Medication nonadherence is a major cause of morbidity, especially in elderly patients.

The product has an estimated market size of $338M for the 12 months ending August 2018 according to officials with IQVIA.

If approved for this indication, dupilumab (Dupixent) will be the first systemic biologic medicine to treat adolescents with moderate-to-severe atopic dermatitis.

The FDA has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) in adolescent patients aged 12 to 17 years with moderate-to-severe atopic dermatitis.

Targeting interleukin (IL)-17A and IL-22 proteins may help delay the development of hepatic fibrosis.

Officials with the FDA have approved a new opioid, (Dsuvia, AcelRx Pharmaceuticals), sparking some controversy in the media that the opioid has potential for abuse.

Top news of the day from across the health care landscape.

Stigma may cause undiagnosed individuals with HIV to go unidentified and fail to get quality care and treatment.

Findings showed that LAIV was more effective in those vaccinated in both the enrollment season and the prior season than in those vaccinated only in the enrollment season.

With the growth of specialty medications and the high-touch care that is needed to ensure optimal outcomes, a niche market focused on providing ancillary services for these drugs has grown in popularity.

Officials with the FDA have approved a new opioid, (Dsuvia, AcelRx Pharmaceuticals), sparking some controversy in the media that the opioid has potential for abuse.

Study identifies potential risk factors for chemotherapy-induced febrile neutropenia in patients with cancer.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Several large investigations have demonstrated the considerable efficacy of TDF/FTC taken daily or intermittently, reducing the risk of HIV acquisition by more than 95% in high-risk individuals.

Lorlatinib approved for patients with ALK-positive metastatic NSCLC who have progressed on crizotinib (Xalkori) and at least 1 other ALK inhibitor for metastatic disease.

This cannabidiol oral solution can be prescribed in the United States to treat seizures associated with Dravet or Lennox-Gastaut syndrome.

The FDA has granted lorlatinib (Lorbrena) an accelerated approval for the treatment of patients with ALK-positive metastatic non–small cell lung cancer (NSCLC) who have progressed on 1 or more ALK tyrosine kinase inhibitors.

Although HPV vaccination rates have steadily increased in recent years, more work is needed in this area to effectively reduce HPV-associated cancer, according to a new report release by the President’s Cancer Panel.

Officials with the FDA have approved Coherus BioSciences’ Udenyca (pegfilgrastim-cbqv) for patients with cancer receiving myelosuppressive chemotherapy. The drug is a biosimilar to Amgen’s Neulasta (pegfilgrastim).

Officials with the FDA have approved Coherus BioSciences’ Udenyca™ (pegfilgrastim-cbqv) for patients with cancer receiving myelosuppressive chemotherapy. The drug is a biosimilar to Amgen’s Neulasta (pegfilgrastim).

The approval is based on data from a multicenter trial in which patients were randomized 2:1 to receive either 30 mcg of the sufentanil sublingual tablet as needed, or placebo, with treatment limited up to 48 hours following the procedure.

The committee jointly voted 21-2 against recommending approval, noting that the benefit-risk profile was not adequate to support approval.

This approval marks the first and only oral film approved by the FDA to treat seizures associated with Lennox-Gastaut syndrome.

Hyperkalemia increased the risk of 30-day readmissions.